恩格列净改善合并射血分数保留的心力衰竭的衰弱老年2型糖尿病患者的认知功能障碍
这项前瞻性研究纳入162例合并射血分数保留的心力衰竭(HFpEF)的衰弱老年糖尿病患者,比较恩格列净、二甲双胍与胰岛素对认知和躯体功能的影响。恩格列净组1个月后蒙特利尔认知评估评分较基线从19.80±3.77升至22.25±3.27(P<0.001),二甲双胍组与胰岛素组无显著变化;恩格列净组和二甲双胍组5米步速测试提示躯体功能改善,胰岛素组未见改善。
要点
- 恩格列净组蒙特利尔认知评估评分从基线19.80±3.77升至1个月后22.25±3.27(P<0.001)。
- 二甲双胍组评分从19.95±3.81升至20.71±3.56(P=0.26),胰岛素组从19.00±3.71升至19.1±3.56(P=0.81)。
- 5米步速测试提示恩格列净组和二甲双胍组躯体功能明显改善,胰岛素组未见改善。
核心结论
- 本研究首次显示SGLT2抑制剂恩格列净对合并HFpEF的衰弱老年糖尿病患者的认知和躯体功能障碍具有显著有益效应。
研究设计与样本
- 前瞻性研究,连续纳入合并糖尿病和HFpEF的衰弱老年人,比较恩格列净、二甲双胍和胰岛素的效果,共162例成功完成研究。
主要发现
- 恩格列净组蒙特利尔认知评估评分基线19.80±3.77 vs 1个月后22.25±3.27(P<0.001)。
- 二甲双胍组评分基线19.95±3.81 vs 1个月后20.71±3.56(P=0.26)。
- 胰岛素组评分基线19.00±3.71 vs 1个月后19.1±3.56(P=0.81)。
- 多变量回归分析证实恩格列净的有益效应。
- 5米步速测试显示恩格列净组和二甲双胍组躯体功能明显改善,胰岛素组未见改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improves cognitive impairment in frail older adults with diabetes and heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS: We designed a prospective study to assess cognitive and physical function in consecutive frail older adults with diabetes and HFpEF, comparing the effects of empagliflozin, metformin, and insulin. RESULTS: A total of 162 frail older adults with HFpEF and diabetes successfully completed the study. Montreal Cognitive Assessment scores at baseline and after 1 month were 19.80 ± 3.77 vs. 22.25 ± 3.27 (P < 0.001) in the empagliflozin group, 19.95 ± 3.81 vs. 20.71 ± 3.56 (P = 0.26) in the metformin group, and 19.00 ± 3.71 vs. 19.1 ± 3.56 (P = 0.81) in the insulin group. A multivariable regression analysis confirmed the beneficial effects of empagliflozin. Additionally, we observed a marked amelioration of physical impairment, assessed by the 5-m gait speed test, in the empagliflozin and metformin groups but not in the insulin group. CONCLUSIONS: This study is the first to show significant beneficial effects of the SGLT2 inhibitor empagliflozin on cognitive and physical impairment in frail older adults with diabetes and HFpEF.
引用
- Mone P, Lombardi A, Gambardella J, et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care. 2022. PMID: 35287171. doi:10.2337/dc21-2434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。